comprises at least three polymorphisms.

7.

2

1

CI	A 1	ra.	1	٥.
CL	Λ.	LΣV	1	5:

1	1.	A meth	od for	assessing prostanoid response status in an individual to be
2	tested comprising			
3		(a)	comp	aring
4			(i)	a test polymorphic pattern comprising at least one
5				polymorphic position within a prostaglandin receptor gene
6				of the individual, with
7			(ii)	a reference polymorphic pattern derived from a population
8				of individuals exhibiting a predetermined prostanoid
9	true de la constante de la con			response status; and
10	e de la companya de l	(b)	conch	iding whether the individual possesses the prostanoid
11	response status base	d on whet	her th	e test pattern matches the reference pattern.
1	2.	The me	thod a	ccording to claim 1, wherein the predetermined prostanoid
2	response status is pr	edispositio	on to g	glaucoma.
1	3.	The me	thod a	ccording to claim 1, wherein the predetermined prostanoid
2	response status is pr	edispositio	on to l	ypertension.
	· • .			·
1	4.	The me	thod a	ccording to claim 1, wherein the predetermined prostanoid
2	response status is res	sponsivity	to syr	athetic prostaglandin analogues.
1	5.	The me	thod a	ccording to claim 1, wherein the reference pattern
2	comprises at least ty	vo polymo	orphis	ms.
1	6.	The me	thod a	ccording to claim 5, wherein the reference pattern

A kit for assessing prostanoid response status comprising

-47-

2	(a) sequence determination oligonucleotides and
3	(b) sequence determination reagents,
4	wherein the primers are selected from the group consisting of primers that hybridize to or
5	immediately adjacent to a polymorphic position in a human prostaglandin receptor gene.
1	8. The kit of claim 7, wherein the prostaglandin receptor is an FP
2	prostaglandin receptor.
_	prosungianam roospios.
1	9. The kit of claim 8, wherein the polymorphism is of a nucleotide selected
2	is an all group community of macrosaco managers as, so, co, co, and for 2 of a flaction acid
3	sequence as depicted in Figure 1 (SEQ ID NO:1).
1	10. The kit of claim 7, wherein the prostaglandin receptor is an EP-1
2	prostaglandin receptor.
1	11. The kit of claim 7, wherein the polymorphism is of a nucleotide selected
2	from the group consisting of nucleotide numbers 211, 264, 689, 690, 767, 816, and 999 of a
3	nucleotide sequence as depicted in Figure 2 (SEQ ID NO:3).
1	12. An isolated nucleic acid encoding a human FP prostaglandin receptor
2	comprising the sequence depicted in Figure 1 (SEQ ID NO:2), wherein said sequence comprises
3	one or more residues selected from the group consisting of: a T residue at position 63; a T
4	residue at position 213; an A residue at position 465; a G residue at position 573; and a G residue
5	at position 1012.
	· ·
1	13. A nucleic acid as defined in claim 12, wherein said nucleic acid is DNA.
1	14 A public acid as defined in claim 12 Wherein said nucleic acid is DNA

1

22.

1		15	5.	A recombinant DNA vector comprising a nucleic acid as defined in claim
2		12 operably links	ed to	a transcription regulatory element.
1		16	6.	A cell comprising a DNA vector as defined in claim 15, wherein said cell
2		is selected from t	the gr	roup consisting of bacterial, fungal, plant, insect, and mammalian cells.
		1.0	-	A
1		17		A method for producing a polypeptide, said method comprising culturing a
2				m 16 under conditions that permit expression of one or more polypeptides
3	antei.	encoded by said	nucle	eic acid.
1	t.i	18	8.	An isolated polypeptide having an amino acid sequence depicted in Figure
2		1 (SEQ ID NO:2	!), wh	erein said polypeptide comprises any one or both of residues Ile ₁₅₅ and
3		Val ₃₃₈ .		
	į.			
1	The state of the s	19	9.	A method of screening for a candidate compound that interacts with a
2		human FP prosta	ıgland	in receptor comprising detecting binding of the polypeptide of claim 18
3	L.	with the compou	ınd.	
1		20	0.	An isolated nucleic acid encoding a human EP-1 prostaglandin receptor
2		comprising the se	equer	nce depicted in Figure 2 (SEQ ID NO:4), wherein said sequence comprises
3		one or more resid	dues s	selected from the group consisting of: a G residue at position 211; a T
4		residue at positio	on 264	4; a T residue at position 689; an A residue at position 690; a G residue at
5		position 767; a T	resio	due at position 816; and an A residue at position 999.
1		21	1.	A nucleic acid as defined in claim 20, wherein said nucleic acid is DNA.

A nucleic acid as defined in claim 20, wherein said nucleic acid is RNA.

4

-49-

4	
1	23. A recombinant DNA vector comprising a nucleic acid as defined in claim
2	20 operably linked to a transcription regulatory element.
1	24. A cell comprising a DNA vector as defined in claim 23, wherein said cell
2	is selected from the group consisting of bacterial, fungal, plant, insect, and mammalian cells.
1	25. A method for producing a polypeptide, said method comprising culturing a
2	cell as defined in claim 24 under conditions that permit expression of one or more polypeptides
3	encoded by said nucleic acid.
1	26. An isolated polypeptide having an amino acid sequence depicted in Figure
2	2 (SEQ ID NO:4), wherein said polypeptide comprises any one or more of residues Ala ₇₁ ; Leu ₂₃₀ ;
3	and Arg ₂₅₆ .
1	27. A method of screening for a candidate compound that interacts with a
2	human EP-1 prostaglandin receptor comprising detecting binding of the polypeptide of claim 26
3	with the compound.